HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
EYE ON CHINA
Mab-Venture Biopharma & Thermo Fisher Establish Asia Pacific's First "SmartFactory" for Antibody Drugs

On 20th April 2017, Mab-Venture and Thermo Fisher have formed a strategic cooperation agreement, under which they will jointly establish an antibody drug "SmartFactory" to promote the development of biopharmaceuticals in Asia.

At the 2017 China (Guangdong) & U.S. Investment Cooperation and Communication Meeting held in Guangzhou, Thermo Fisher, the world leader in scientific services, and Mab-Venture Biopharm Co., Ltd. (Mab-Venture), signed a strategic cooperation agreement in the witness of Chunhua Hu: The Secretary of the Guangdong Provincial Party Committee.

The two companies will establish ‘Mab-Venture & Thermo Fisher Scientific Antibody Technology Showcase and Service Center’ at Guangzhou International Bio Island ("Bio Island"). The center will be the first in Asia Pacific and a world leading intelligent antibody plant utilizing SmartFactory. SmartFactory is an automated control solution developed by Thermo, which optimizes plant-wide resource utilization, integrates manufacturing (batch) information, and facilitates training and validation record management for single-use system facilities. Once established, the Center will provide a variety of antibody drug services including Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) services.

Mab-Venture and Thermo will collaborate to bring the world's leading solution to China to achieve the goal of "one place", "one bottle of medicine". The agreement will promote local biopharmaceutical companies (especially CROs & CMOs) to maintain product quality and compliance, while greatly enhancing the speed of R&D and reducing costs, so as to facilitate the rapid development of the whole industry, and ultimately benefit the majority of patients.

The collaboration of Thermo Fisher and Mab-Venture on Guangzhou’s Bio Island will also help further fuel the eco-system and promote Guangdong and China’s biotechnology capabilities. It is also an important milestone in the process of the Guangzhou government strengthening Sino-US ties in science and technology after the signing of a comprehensive strategic cooperation agreement with Thermo in 2016.

"The company is located in various cities in Guangdong and has a solid foundation of cooperation with Guangzhou," said Gianluca Pettiti, president of Thermo Fisher China. "In the 'Bio Island' which also is the 'Accelerated Land' of Innovation, we hope to strengthen ties with local partners in the field of biopharmaceuticals, precision medicine and other areas to bring success and practice the long-term commitment 'rooted in China, serve for China'.”

Dr. George Wang, the founder and CEO of Mab-Venture said, “We will further deepen the strength and competitiveness of a variety of antibody contract development (CRO) and contract manufacturing (CMO) services, which is in line with the vision of the Chinese government to enhance the country’s innovative biologics capabilities. We are delighted to have in-depth cooperation with Thermo, especially by introducing SmartFactory, a new intelligent force to strengthen our industry's leading position. The application of this platform can not only shorten facility construction time, but also reduce production costs, improve overall R&D and manufacturing capabilities, in order to create a biotechnology company committed to the whole industry chain.

Source: Mab-Venture Biopharma

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy